Lilly says Phase 3b ADtouch trial shows EBGLYSS beats placebo in hand and foot atopic dermatitis skin clearance at Week 16

Bitget2026/09/30 12:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Eli Lilly reported Phase 3b ADtouch results for EBGLYSS in moderate-to-severe hand and foot atopic dermatitis.
Late-breaking data will be presented at the EADV Congress running Sept. 30–Oct. 3 in Vienna.
Treatment met key study goals, showing rapid skin clearing with meaningful relief in itch and pain versus placebo.
Patient-reported satisfaction improved, supporting a broader value story beyond clinician-assessed skin outcomes.
Lilly has submitted the findings to the FDA to support a potential label update for localized hand and foot disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: DE60006) on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lilly says Phase 3b ADtouch trial shows EBGLYSS beats placebo in hand and foot atopic dermatitis skin clearance at Week 16

You may also like

Crypto prices